| Buy The Dip: 2 Blue-Chip High Yields Getting Way Too Cheap |
I focus on buying high-quality, high-yielding dividend growth stocks. When they go on sale, I pounce. I share two that are trading at highly compelling opportunities after recent pullbacks. |
seekingalpha.com |
2025-05-16 11:05:00 |
Czytaj oryginał (ang.) |
| ADC Therapeutics to Present at Upcoming Investor Conferences |
LAUSANNE, Switzerland , May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: May 21, 2025 Presentation Time: 10:30-10:55 a.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerTo register for the webcast, click here. |
prnewswire.com |
2025-05-15 11:15:00 |
Czytaj oryginał (ang.) |
| Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 |
Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by end of 2025. Ideaya plans a phase 3 study of darovasertib as a neoadjuvant for uveal melanoma, starting in the first half of 2025. IDE849 is an ADC targeting DLL3 in SCLC and NETs, This program has two catalysts: phase 1 data in Q3 2025 and a new study in H2 2025. |
seekingalpha.com |
2025-05-14 21:30:33 |
Czytaj oryginał (ang.) |
| Agree Realty Announces Pricing of $400 Million of 5.600% Senior Unsecured Notes Due 2035 |
Inclusive of Prior Hedging Activity the All-In Interest Rate of the Notes is 5.35% ROYAL OAK, Mich. , May 14, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its operating partnership, Agree Limited Partnership (the "Operating Partnership"), priced a public offering of $400 million of its 5.600% senior unsecured notes due 2035 (the "Notes"). |
prnewswire.com |
2025-05-14 20:24:00 |
Czytaj oryginał (ang.) |
| ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update |
LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL Cash runway expected to fund multiple catalysts into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland , May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates. |
prnewswire.com |
2025-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) |
ZYNLONTA ® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL Safety and tolerability data were consistent with the known profiles of each agent Updated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at ICML on Friday, June 20 at 9:00 a.m. |
prnewswire.com |
2025-05-14 11:45:00 |
Czytaj oryginał (ang.) |
| 5 U.S. REITs Announce Dividend Increases In April |
Five publicly traded real estate investment trusts in the US announced increases to their regular dividend payments in April, according to S&P Global Market Intelligence data. The total number of publicly traded US REITs that have declared increases to their regular dividends during the first four months of 2025 is 40, representing more than a quarter of the sector. These entities include nine companies, or 47.4%, of the residential REIT industry as well as seven companies, or 38.9%, of the specialty REIT industry. |
seekingalpha.com |
2025-05-14 08:30:00 |
Czytaj oryginał (ang.) |
| Agree Realty Declares Monthly Common and Preferred Dividends |
ROYAL OAK, Mich. , May 13, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share. |
prnewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Hard To Imagine Retirement Income Portfolio Without These 2 Picks |
Typically, investors put a focus on high-yield securities if the goal is to live off from portfolio income streams. These high-yielding securities come from BDC, REIT, MLP, CEF and other value-oriented segments. The common drawback of them is the lack of meaningful income growth and tightly correlated exposures. |
seekingalpha.com |
2025-05-09 13:15:00 |
Czytaj oryginał (ang.) |
| Agree Realty: Premium Valuation, But Still Worth Considering |
Agree Realty has outperformed peers and the S&P 500 since our last update, driven by a strong dividend yield and share price recovery. Even with the greater volatility that the broader market has been experiencing, ADC has remained resilient, but has moved to a premium valuation against peers. Despite a premium valuation, ADC's focus on quality tenants, steady AFFO growth, and strong balance sheet can justify it still being a worthwhile investment. |
seekingalpha.com |
2025-05-09 12:27:14 |
Czytaj oryginał (ang.) |
| A Ranking Of Net-Lease REITs By Investment Spread For Q1 2025 |
In Q1 2025, VICI, GLPI, Agree, and Realty Income generated positive investment spreads and total returns exceeding their cost of equity, making them attractive investments. EPRT and STAG have negative investment spreads and total returns below their cost of equity, making them less favorable investment options. This analysis uses cap rates and the weighted average cost of capital to estimate investment spreads. We also compare total returns to the cost of equity to measure accretion. |
seekingalpha.com |
2025-05-08 15:00:07 |
Czytaj oryginał (ang.) |
| ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 |
LAUSANNE, Switzerland , May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025 and provide operational updates. |
prnewswire.com |
2025-05-08 11:15:00 |
Czytaj oryginał (ang.) |
| Correction Alert: Popular Dividend Growth Stocks Due For A Sharp Pullback |
These 2 popular dividend growth stocks could decline by 10%+. Here's why we're avoiding them. I share two alternative peers that are more reasonably valued. |
seekingalpha.com |
2025-05-07 11:05:00 |
Czytaj oryginał (ang.) |
| Agree Realty: Outperforming Net Lease (Rating Downgrade) |
Economic uncertainty and volatility in 2025 present long-term investment opportunities, especially in high-quality commercial real estate like ADC. ADC has a strong track record, with a compound annual return of over 12% since its 1994 IPO and consistent dividend growth. Despite ADC's impressive portfolio and balance sheet, current high valuations limit upside potential, making it prudent to hold rather than buy at $77 per share. |
seekingalpha.com |
2025-05-07 08:10:44 |
Czytaj oryginał (ang.) |
| Agree Realty: Now That's What I Call A Serious Long-Term Investment |
Agree Realty represents a defensive stock of high quality that investors should consider for long-term income generation because it offers a secure 4% dividend yield and resilient growth. The company has delivered a 4,000% total return since its inception and achieved a 277% total return during the last ten years. The company's exceptional portfolio, with a 99.2% occupancy rate and strategic acquisitions, alongside strong financials, underscores its investment appeal. |
seekingalpha.com |
2025-05-06 04:41:19 |
Czytaj oryginał (ang.) |
| 3 High-Yield Dividend Stocks to Buy in May to Collect Passive Income Every Month |
Most dividend stocks make quarterly payments. That can make it a bit challenging for those seeking regular passive income to help cover their monthly expenses. |
fool.com |
2025-05-05 22:23:00 |
Czytaj oryginał (ang.) |
| Boomers Are Buying 5 Safe Monthly Dividend Stocks Delivering Huge Passive Income |
Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence. |
247wallst.com |
2025-05-05 19:47:04 |
Czytaj oryginał (ang.) |
| 3 Once-In-A-Decade REIT Opportunities |
REITs are priced at the lowest valuations since 2009. After a long bear market, REITs are getting ready to recover. Some REITs will richly reward shareholders. Here are 3 once-in-a-decade opportunities that we are accumulating. |
seekingalpha.com |
2025-04-30 12:15:00 |
Czytaj oryginał (ang.) |
| Agree Realty: The Steady Eddy Monthly Payer You Need Amidst Market Uncertainty |
Agree Realty Corporation offers a solid monthly yield of nearly 3%, a recession-resistant portfolio, and astute management, making it a strong buy despite seeming expensive. Q1 2025 earnings showed robust performance with core FFO and revenue growth, driven by strategic investments and annual rent escalators. The REIT's low AFFO payout ratio of 72% and strong balance sheet with minimal debt until 2028 position ADC well for growth and stability. |
seekingalpha.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 |
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - |
globenewswire.com |
2025-04-28 20:05:00 |
Czytaj oryginał (ang.) |
| Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy |
HONG KONG , Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and differentiated HER3-targeting ADC (antibody-drug conjugate), is Akeso's first ADC drug to enter clinical studies. |
prnewswire.com |
2025-02-27 05:58:00 |
Czytaj oryginał (ang.) |
| OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms |
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) & other tunable drug conjugates (tDC) platf. |
businesswire.com |
2025-02-24 09:25:00 |
Czytaj oryginał (ang.) |
| The State Of REITs: February 2025 Edition |
After a brutal December (-6.85%), the REIT sector averaged negative total returns again in January (-1.29%). Large cap (+0.30%) and mid cap REITs (+0.09%) averaged small gains in January, whereas small caps (-0.95%) and micro caps (-7.80%) started the year in the red. Only 42.58% of REIT securities had a positive total during the first month of 2025. |
seekingalpha.com |
2025-02-21 13:59:38 |
Czytaj oryginał (ang.) |
| Agree Realty: When The Perfect Blend Of Consistency, Reliability, And Quality Meet |
Agree Realty's strong portfolio, minimal exposure to economic downturns, and robust growth potential make it a compelling long-term hold for income-focused investors. Despite recent inflation concerns, ADC's Q4 and full-year performance showcased solid AFFO growth, strong acquisitions, and a well-covered monthly dividend. The REIT's fortress balance sheet, minimal debt maturities, and liquidity of $2 billion position it well for continued growth and potential upside. |
seekingalpha.com |
2025-02-20 12:00:00 |
Czytaj oryginał (ang.) |
| I'm Buying Up To 9% Yield For Recurring Income |
The 4% rule may be outdated due to current inflation and market conditions, making income stocks all the more relevant. I highlight two quality players who offer well-covered dividends and strong business models. Both companies carry strong balance sheets, and could be potentially rewarding for long-term income and growth. |
seekingalpha.com |
2025-02-19 16:00:00 |
Czytaj oryginał (ang.) |
| Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates |
Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) |
globenewswire.com |
2025-02-19 10:35:00 |
Czytaj oryginał (ang.) |
| Agree Realty Vs. Realty Income: Accumulate Both REITs Offering Different Benefits |
Agree Realty and Realty Income are two of my personal REIT holdings. ADC shows better stability and tenant credit quality. ADC's portfolio boasts 68.2% investment-grade tenants and a 99.6% occupancy rate, while O has only 32% investment-grade tenants and a 98.7% occupancy rate. O offers a higher starting dividend yield at 5.8%, but ADC has superior dividend growth, potentially leading to higher long-term income despite its shorter history. |
seekingalpha.com |
2025-02-18 12:51:51 |
Czytaj oryginał (ang.) |
| Want to Collect Some Extra Income Each Month? Buy These 2 Top High-Yield Dividend Stocks. |
Most dividend stocks make quarterly payments. That can make it more challenging for those seeking to align their income with their monthly expenses. |
fool.com |
2025-02-17 12:56:54 |
Czytaj oryginał (ang.) |
| CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 |
NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). |
globenewswire.com |
2025-02-14 09:30:00 |
Czytaj oryginał (ang.) |
| How To Build A $1,000 Monthly Dividend Income Stream From REITs |
REIT dividend yields are historically high. Even high-quality REITs are now offering high dividend yields. We build a REIT portfolio generating $1,000 monthly dividend income. |
seekingalpha.com |
2025-02-13 10:25:00 |
Czytaj oryginał (ang.) |
| Agree Realty Corporation (ADC) Q4 2024 Earnings Call Transcript |
Agree Realty Corporation (NYSE:ADC ) Q4 2024 Earnings Conference Call February 12, 2025 9:00 AM ET Company Participants Reuben Treatman – Senior Director-Corporate Finance Joey Agree – President and Chief Executive Officer Peter Coughenour – Chief Financial Officer Conference Call Participants Ki Bin Kim – Truist Securities Smedes Rose – Citigroup Jenny Li – Morgan Stanley Michael Goldsmith – UBS Rob Stevenson – Janney Capital Upal Rana – KeyBanc Capital Markets Linda Tsai – Jefferies Wes Golladay – Baird Eric Borden – BMO Capital Markets Farrell Granath – Bank of America Rich Hightower – Barclays Haendel St. Juste – Mizuho Operator Good morning, and welcome to the Agree Realty Fourth Quarter 2024 Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-02-12 14:05:17 |
Czytaj oryginał (ang.) |
| Q4 Earnings Update: Sell Agree Realty And Buy This REIT Instead |
Agree Realty's focus on high-quality investment-grade tenants, ground leases, and aggressive acquisitions initially made it a superior investment compared to Realty Income. Despite ADC's strong business model, its stretched valuation and lower expected returns prompt a downgrade to SELL. ADC's high valuation implies limited price appreciation, making it less attractive compared to peers and the market. |
seekingalpha.com |
2025-02-12 05:28:51 |
Czytaj oryginał (ang.) |
| Agree Realty (ADC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Agree Realty (ADC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-11 21:01:28 |
Czytaj oryginał (ang.) |
| Agree Realty (ADC) Surpasses Q4 FFO and Revenue Estimates |
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.04 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to FFO of $1 per share a year ago. |
zacks.com |
2025-02-11 20:36:11 |
Czytaj oryginał (ang.) |
| Agree Realty Corporation Reports Fourth Quarter and Full Year 2024 Results |
Provides Initial 2025 AFFO Per Share Guidance of $4.26 to $4.30 ROYAL OAK, Mich. , Feb. 11, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced results for the quarter and full year ended December 31, 2024. |
prnewswire.com |
2025-02-11 18:05:00 |
Czytaj oryginał (ang.) |
| F5 Redefines ADC for the AI Era |
SEATTLE--(BUSINESS WIRE)--F5 (NASDAQ: FFIV) today outlined its vision on how Application Delivery Controllers (ADCs) must transform to meet the extraordinary demands of modern and AI-powered applications. With a platform-based approach that delivers flexibility in form factor, management capabilities, and advanced control over every aspect of application security and delivery, F5 is leading the way and developing this next generation of ADCs. “The rise of AI and modern applications demands a fu. |
businesswire.com |
2025-02-11 09:00:00 |
Czytaj oryginał (ang.) |
| Retirees Seeking Safe Monthly Passive Income Should Buy These 5 High-Yield Favorites |
Most dividend investors seek solid passive income streams from quality dividend stocks. |
247wallst.com |
2025-02-09 09:41:15 |
Czytaj oryginał (ang.) |
| Better Monthly Dividend Stock: Realty Income vs. Agree Realty |
At the core, Agree Realty (ADC 0.27%) and Realty Income (O -0.26%) are very similar real estate investment trusts (REITs). But they aren't interchangeable. |
fool.com |
2025-02-07 06:25:00 |
Czytaj oryginał (ang.) |
| Buy The Dip: Big Dividends Getting Way Too Cheap |
My strategy involves buying high-quality, high-yield stocks at discounts, holding until they re-appreciate, and then selling to reinvest in undervalued stocks. I share some of the most attractive, high-quality big dividend stocks available right now. I detail why they are good buys. |
seekingalpha.com |
2025-02-06 18:30:00 |
Czytaj oryginał (ang.) |
| Agree Realty Declares Monthly Common and Preferred Dividends |
ROYAL OAK, Mich. , Feb. 6, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.253 per common share. |
prnewswire.com |
2025-02-06 18:05:00 |
Czytaj oryginał (ang.) |
| Agree Realty: Still A Marginal Buy Case To Be Made Now |
A few months ago, Agree Realty upped its monthly dividend per share. The REIT delivered in the third quarter and looks positioned to keep generating solid AFFO per share growth. Agree Realty's credit rating was recently upgraded to BBB+ on a stable outlook by S&P. |
seekingalpha.com |
2025-01-04 09:00:00 |
Czytaj oryginał (ang.) |
| ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
LAUSANNE, Switzerland , Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 20,000 of the Company's common shares to two new employees on January 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. |
prnewswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| 3 High-Yield Asset Classes For Dividend Investors In 2025 |
Traditional dividend valuation methods may not apply to all asset classes. Business Development Companies like Blue Owl Capital offer high yields through diverse debt investments, benefiting from higher interest rates and defensive portfolio structures. REITs, despite current underperformance, present opportunities for high yields and potential capital appreciation, especially with future interest rate cuts. |
seekingalpha.com |
2025-01-01 22:29:45 |
Czytaj oryginał (ang.) |
| ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma |
LAUSANNE, Switzerland , Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021. |
prnewswire.com |
2024-12-30 18:30:00 |
Czytaj oryginał (ang.) |
| What Are The Top REITs For 2025? |
REITs are offering a once-in-a-decade opportunity. They are heavily discounted and some enjoy strong catalysts in 2025. This could lead to significant upside. Here are some of my top picks. |
seekingalpha.com |
2024-12-30 10:25:00 |
Czytaj oryginał (ang.) |
| IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors |
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC) DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respectively 85% and 20-40% Rational combination opportunities with IDEAYA's DNA Damage Repair (DDR) clinical pipeline, including Phase 1 PARG inhibitor IDE161 Targeting US IND filing for SHR-4849 in H1 2025 SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Dec. 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program with Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
prnewswire.com |
2024-12-29 08:00:00 |
Czytaj oryginał (ang.) |
| 2 REITs Investors Should Own In 2025 |
The REIT market has something for everyone. There are income, growth, and deep value opportunities. But a few REITs have it all. We highlight 2 such REITs to own in 2025. |
seekingalpha.com |
2024-12-28 10:25:00 |
Czytaj oryginał (ang.) |
| 8 Stocks I'm Buying As I Hone My Buying Strategy For 2025 |
I visualize my portfolio as a galley ship with rowers (steady compounders) and sails (high-yielding securities) for balanced growth and income. In 2025, my goal is to refocus on rowers to enhance dividend growth, using Schwab US Dividend Equity ETF (SCHD) as a primary vehicle. I've sold high-risk stocks and reinvested in higher-yielding, safer options, but my portfolio is now too weighted towards immediate income. |
seekingalpha.com |
2024-12-28 10:05:00 |
Czytaj oryginał (ang.) |
| Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. |
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline |
globenewswire.com |
2024-12-27 18:05:00 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Dividend Stocks to Buy With $200 Right Now |
The S&P 500 dipped last week after the Federal Reserve said it's planning to slow the pace of its interest rate cuts in 2025. However, the index is still up 24% as we head toward the end of the year. |
fool.com |
2024-12-26 11:15:00 |
Czytaj oryginał (ang.) |
| The Smartest Dividend Growth Stocks to Buy With $500 Right Now |
Real estate investment trusts (REITs) have been out of favor on Wall Street for the past couple of thanks to interest rate volatility. That's understandable since higher rates increase financing costs for REITs. |
fool.com |
2024-12-26 06:15:00 |
Czytaj oryginał (ang.) |
| 1 REIT To Sell And 1 Strong Buy |
Not all REITs are equal. The asset quality can differ greatly from one REIT to another. I highlight a good example of that. |
seekingalpha.com |
2024-12-24 10:35:00 |
Czytaj oryginał (ang.) |
| Agree Realty: Three Ways To Invest In A Net Lease Leader |
ADC offers three investment options: common shares, preferred shares, and bonds, each with varying yields and risk profiles. We compare these three opportunities amidst the backdrop of a rising ten year treasury rate. ADC's business remains strong, but a sector leading valuation should make investors ask whether the common shares are the best opportunity. |
seekingalpha.com |
2024-12-23 16:35:29 |
Czytaj oryginał (ang.) |
| Lessons Learned Summed Up In One Simple Sentence |
My journey on Seeking Alpha began after personal financial setbacks, but persistence and relevance helped me build a strong community and career. I highlight Iron Mountain, Agree Realty, and STAG Industrial as top REIT picks, emphasizing their strong business models and growth potential. Iron Mountain's shift to a REIT and focus on data centers has driven significant growth, though shares are currently overvalued. |
seekingalpha.com |
2024-12-23 09:00:00 |
Czytaj oryginał (ang.) |
| 3 Reasons to Buy Agree Realty Stock Like There's No Tomorrow |
Are you shopping around for a new dividend payer? Perhaps you've heard some of the recent buzz suddenly surrounding a relatively small company called Agree Realty (ADC 1.05%). |
fool.com |
2024-12-22 07:55:00 |
Czytaj oryginał (ang.) |
| 3 Low-Risk Dividend Stocks to Buy for Durable Passive Income for 2025 and Beyond |
Dividend stocks come in all different forms. Some companies offer higher dividend yields along with higher risk profiles, while others have lower yields but deliver more growth. |
fool.com |
2024-12-22 07:28:00 |
Czytaj oryginał (ang.) |
| 10 Stocks I'm Buying As REITs Have Never Looked So Good |
The recent market selloff, driven by the Fed's revised rate-cut forecast, has made high-quality REITs attractively priced for long-term dividend growth investors. Despite poor stock price performance, REITs have strong fundamentals, with favorable earnings yield spreads and dividend yields compared to the broader market. REITs are undervalued due to being treated as bond proxies, but their strong commercial real estate fundamentals and historical outperformance post-Fed rate cuts suggest a buying opportunity. |
seekingalpha.com |
2024-12-21 10:05:00 |
Czytaj oryginał (ang.) |
| Agree Realty Stock: Buy, Sell, or Hold? |
In 2022 and 2023, rising interest rates drove up the yields of low-risk fixed income investments like Treasury bills, bonds, and CDs, which made them more appealing than dividend stocks. But as interest rates decline, those fixed income yields are shrinking and driving more investors back toward higher-yielding dividend stocks. |
fool.com |
2024-12-21 08:00:00 |
Czytaj oryginał (ang.) |
| Want Decades of Passive Income? 3 Stocks to Buy Right Now |
Are you looking for reliable long-term investment income? Consider starting your search here, with a closer look at three great dividend stocks that would be at home in nearly any investor's portfolio. |
fool.com |
2024-12-21 06:24:00 |
Czytaj oryginał (ang.) |
| Should You Buy This Millionaire-Maker Stock Instead of Agree Realty? |
Agree Realty (ADC 1.05%) has been a popular stock in 2024, with a share price gain of more than 15%. That's roughly three times the return of the average real estate investment trust (REIT). |
fool.com |
2024-12-21 05:48:00 |
Czytaj oryginał (ang.) |